Topical Imiquimod in the Treatment of Conjunctival Actinic Keratosis.

Journal Article (Journal Article)

Conjunctival actinic keratosis is rare and difficult to treat, as recurrences are common. Imiquimod, an immune response modulator, is currently Food and Drug Administration-approved for cutaneous actinic keratosis and superficial basal cell carcinomas. Emerging reports have shown it to be effective in treating some periocular and conjunctival lesions. The authors present a case of a 68-year-old white man with recurrent actinic keratosis involving the pretarsal conjunctiva, which was successfully treated with 5% topical imiquimod following previous failure with cryotherapy and interferon α-2b. The patient had ocular irritation that resolved on cessation of treatment. To the authors' knowledge, this is the first report of conjunctival actinic keratosis being treated with and successfully eradicated by topical imiquimod.

Full Text

Duke Authors

Cited Authors

  • Rowlands, MA; Giacometti, JN; Servat, J; Materin, MA; Levin, F

Published Date

  • 2017

Published In

Volume / Issue

  • 33 / 1

Start / End Page

  • e21 - e23

PubMed ID

  • 25853505

Electronic International Standard Serial Number (EISSN)

  • 1537-2677

Digital Object Identifier (DOI)

  • 10.1097/IOP.0000000000000432


  • eng

Conference Location

  • United States